Boehringer Ingelheim Previews New Product Launches Expected in 2025

Boehringer Ingelheim has released data on its patient reach, sales, and investments during 2024, and is looking ahead to the company’s anticipated offerings for the rest of 2025.

In a press release on April 22, 2025, the biopharmaceutical company said the 66 million patients it reached in 2024 represented an 8% increase over 2023, with R&D investments rising to €6.2 billion (US$7.02 billion), representing 23.2% of group net sales (1).

Frank Hübler, member of the board of managing directors with responsibility for Finance, said that figure was indicative of an upward trend.

“If we look at the past five years, Boehringer Ingelheim has invested approximately €25 billion (US$28.3 billion) in R&D,” Hübler said in the release (1). “With the innovations currently in our pipeline, we will further increase investments in R&D in the years to come.”

Boehringer Ingelheim is active in both human and animal health; in 2024, its sales in the human pharma sector rose by 7% to €21.9 billion (US$24.8 billion), led by treatments for chronic kidney disease, type 2 diabetes, and heart failure (€8.4 billion, US$9.5 billion), and idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases (€3.8 billion, US$4.3 billion) (1).

The company’s human pharma pipeline includes more than 10 new Phase II and III trials over the next 12 to 18 months—to nearly the end of 2026—and R&D spending in that area in 2024 totaled €5.7 billion (US$6.46 billion), representing more than a quarter (27.6%) of Boehringer Ingelheim’s business unit’s net sales (1).

For 2025, Boehringer Ingelheim is preparing product launches that the company said will advance care for patients with idiopathic or progressive pulmonary fibrosis, along with the first orally administered targeted therapy for patients with previously treated human epidermal growth factor receptor 2 (HER2)-mutated lung cancer (1).

“As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,” said Hubertus von Baumbach, chairman of the board of managing directors, in the press release (1). “It is important that we use every opportunity to bring these new treatments to patients as fast as possible—this is our number one priority.”

In the January/February 2025 issue of Pharmaceutical Technology®, one of Boehringer Ingelheim’s partnership efforts was spotlighted: its deal with Gubra, a Denmark-based, pre-clinical contract research organization/biotech focusing on peptide-based therapies (2). Gubra is developing four anti-obesity agents in conjunction with Boehringer Ingelheim, including two clinical programs with a long-acting neuropeptide Y receptor type 2 (NPY2R) agonist, BI 1820237—of which Boehringer Ingelheim discontinued its development in October 2024—and a triple agonist.

Another Boehringer Ingelheim partnership, with OSE Immunotherapeutics, yielded the candidates BI 765063 and BI 770371 (anti-signal-regulating protein alpha [SIRPα] monoclonal antibody on CD47/SIRPα pathway), developed for treatment of advanced solid tumors, as reported at the time of the announcement of a strategic partnership between OSE and AbbVie in February 2024 (3).

References

1. Boehringer Ingelheim. Boehringer Ingelheim Reaches More Patients in 2024 and Prepares New Medicine Launches. Press Release. April 22, 2025.
2. Barton, C. Next-Generation Anti-Obesity Medicines. Pharmaceutical Technology 2025, 49 (1) 16–17.
3. Mirasol, F. AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation. PharmTech.com, March 6, 2024.